Navigation Links
BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
Date:9/13/2012

RALEIGH, N.C., Sept. 13, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced a positive outcome of the Company's pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX), which is being developed for the potential treatment of opioid dependence and utilizes the patented BioErodible MucoAdhesive (BEMA) technology to deliver buprenorphine combined with the opioid antagonist naloxone.  Based on the positive outcome of this study, BDSI continues to anticipate that it will be in a position to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BNX during the second quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

The study, BNX-103, was designed to compare the relative bioavailability of buprenorphine and naloxone between BNX and the reference product, Suboxone, which is currently approved for the maintenance treatment of opioid dependence.  Based on the FDA agreed upon 505(b)(2) pharmacokinetic regulatory pathway for the BNX program, the goals of the study were to demonstrate that two key pharmacokinetic parameters, maximum drug plasma concentration (Cmax) and total drug exposure (area under the curve or AUC), for buprenorphine were comparable to Suboxone, and that the same parameters for naloxone were similar or less than Suboxone.  These goals were achieved in the study. 

"We are pleased with the outcome of this study and believe, based on our prior discussions with FDA, that the data supports a key component for our NDA," said Dr. Andrew Finn, Executive Vice President of Product Development.  "The positive results of this study once again demonstrate the value and versatility of our BEMA drug delivery technology and its ability to effectively and efficie
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
10. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
11. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  Legendary actor and director ... new PBAFacts campaign designed to educate and encourage patients ... about Pseudobulbar Affect (PBA) and to speak with their ... actor has the ability to cry and laugh on ... control experienced by people living with PBA episodes. ...
(Date:5/1/2015)... Semler Scientific, Inc. (Nasdaq: SMLR ), ... and markets products that assist healthcare providers in monitoring ... for the first quarter ended March 31, 2015. ... reported continued progress with year over year growth of ... 14%," said Doug Murphy-Chutorian , M.D., chief executive ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
(Date:5/3/2015)... It is not too late to register to take part in ... Anne Been in Arnold, Missouri on May 9, 2015. Family ... her loving memory. It has benefited the renowned Brain Aneurysm Foundation ... Lissa suffered a brain aneurysm . After two operations and ... is designed to serve as a remembrance of her and to ...
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... May 02, 2015 As a ... issues of the face, neck and décolleté, radiofrequency ... with real potential for the success of vulvovaginal ... ThermiHealth Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical ... ACGE, concluded that ThermiGyn’s temperature controlled radio frequency, ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... that enables a surgeon to perform laparoscopic gall bladder and ... computer and video monitor. The surgeon can use hand grips ... arms that can perform the surgery using a variety of ... by Intuitive Surgical, Inc., of Mountain View, Calif., is the ...
... Lung, and Blood Institute (NHLBI) and the National High ... recommendations to treat Hypertension.,Control of systolic blood pressure is ... is a crucial message for health care providers, patients, ... lowering systolic blood pressure to less than 140 mm ...
... from June issue of the American Journal of Epidemiology ... rates than taller people from most causes except cancer. ... women undertaken by Dr.Pekka Jousilahti and his colleagues from ... was found that there was an association between adult ...
... high levels of cholesterol but low levels that are making ... Cholesterol maybe linked to depression and violent behavior. A new ... up to seven times more likely to report symptoms of ... Center in Durham, N.C. Said, "I think that ...
... ,Death Rates Higher for Those Without This Symptom. As many ... or during a heart attack, a study published in The ... diabetics and others who belong to groups likely to have ... such pains. ,The report examined symptoms in more than 400,000 ...
... of the most common cancers in women. If it is ... The Pap smear is the standard screening method for the ... cervical cells. ,Two strains of the human papilloma virus (HPV) ... but not all women who test positive, develop the disease. ...
Cached Medicine News:
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: